Efficasy, safety, and pharmacokinetics results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Wilebrand Factor (WVF)/factor VIII (FVIII) concentrate (Voncento) in subjects with hemophilia A (the SWIFT-HA Study)